biostudies-literatureArai HGloria Borges Wunderglo FoundationDhont Family FoundationNational Cancer InstituteNCI NIH HHS113914https://www.ebi.ac.uk/biostudies/studies/S-EPMC11323978biostudies-literatureUnknown201<h4>Background</h4>CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC).<h4>Material and methods</h4>Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts. A dataset of specimens submitted to a commercial CLIA-certified laboratory was utilized to characterize molecular profiles of CDC37-high (top qEuropean journal of cancer (Oxford, England : 1990)Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.PMC11323978U10 CA180882P30 CA014089UG1 CA239758UG1 CA180830UG1 CA233163U10 CA180821U10 CA180888UG1 CA233373Kubota YWeinberg BAMichael Korn WIzawa NDoi AWang JMillstein JGoel SBaca YInnocenti FSoni SVenook APDenda TMarshall JHorie YAlgaze SLenz HJBattaglin FScott AJXiu JGoldberg RMHwang JJOu FSHall MJJayachandran PZhang WYang YUmemoto KLou ESunakawa YArai HTakeda HfalsePredictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.<h4>Background</h4>CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC).<h4>Material and methods</h4>Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts. A dataset of specimens submitted to a commercial CLIA-certified laboratory was utilized to characterize molecular profiles of CDC37-high (top q2024-01-01T00:00:00Z2024 Apr2026-06-01T05:48:15.085Z2026-04-08T09:36:22.572ZS-EPMC113239783835949510.1016/j.ejca.2024.113914